SCHEMBL31679342

SCHEMBL31679342

CC(C)C[C@H](NC(=O)[C@@H](N)C1CCCCC1)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 5/20 0.46
▸ MME P08473 4/20 0.40
▸ CPA1 P15085 2/20 0.40
▸ ACE2 Q9BYF1 2/20 0.40
▸ CPB2 Q96IY4 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ FNTA P49354 1/20 0.39
▸ FNTB P49356 1/20 0.39
▸ PGGT1B P53609 1/20 0.39
▸ ALOX15 P16050 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ PTGS2 P35354 1/20 0.39
▸ THPO P40225 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31679469 0.84 FNTA (0.49) ACEMMECPA1ACE2CPB2
SCHEMBL30010989 0.81 ACE (0.56) ACEMMEALDH1A1MEN1LMNA
SCHEMBL30311049 0.81 ACE (0.56) ACEMMEALDH1A1MEN1LMNA
SCHEMBL30010855 0.81 ACE (0.56) ACEMMEALDH1A1MEN1LMNA
SCHEMBL30011110 0.81 ACE (0.56) ACEMMEALDH1A1MEN1LMNA
SCHEMBL30010902 0.81 ACE (0.56) ACEMMEALDH1A1MEN1LMNA
SCHEMBL30288000 0.81 ACE (0.56) ACEMMEALDH1A1MEN1LMNA
SCHEMBL29721145 0.80 ACE (0.54) ACEMMEALDH1A1MEN1LMNA
SCHEMBL31688084 0.79 CPB2 (0.50) ACEMMECPA1ACE2CPB2
SCHEMBL31097756 0.78 ACE (0.51) ACEMMEALDH1A1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4610269-A1 UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE 3B Pharmaceuticals GmbH (DE) 2025-09-03 — — EP disclosed
Send feedback